(AOF) – Beyfortus reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% in infants under six months of age, compared to infants who had not been immunized against RSV, according to the results interim results of an ongoing study published in The Lancet. These results are part of the three-year Nirse-Gal study carried out in Galicia (Spain), as part of a collaboration with the General Directorate of Public Health of the Regional Administration of the Autonomous Community of Galicia (Xunta de Galicia) and Sanofi.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
